Isosulfan Blue


Auromedics Pharma Llc
Human Prescription Drug
NDC 55150-240
Isosulfan Blue is a human prescription drug labeled by 'Auromedics Pharma Llc'. National Drug Code (NDC) number for Isosulfan Blue is 55150-240. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Isosulfan Blue drug includes Isosulfan Blue - 50 mg/5mL . The currest status of Isosulfan Blue drug is Active.

Drug Information:

Drug NDC: 55150-240
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Isosulfan Blue
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Isosulfan Blue
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Auromedics Pharma Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection, Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ISOSULFAN BLUE - 50 mg/5mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:SUBCUTANEOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 02 Feb, 2016
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 21 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA206831
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:AuroMedics Pharma LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0355150240050
UPC stands for Universal Product Code.
UNII:39N9K8S2A4
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
55150-240-056 VIAL in 1 CARTON (55150-240-05) / 5 mL in 1 VIAL02 Feb, 2016N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Isosulfan blue isosulfan blue isosulfan blue isosulfan blue inner salt sodium phosphate, dibasic, dihydrate potassium phosphate, monobasic water

Drug Interactions:

7 drug interactions no drug interactions have been identified with isosulfan blue 1%. no drug interactions have been identified for isosulfan blue 1% (7).

Indications and Usage:

1 indications and usage isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. it is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities (1.1). 1.1 lymphatic vessel delineation isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. it is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities.

Warnings and Cautions:

5 warnings and precautions life-threatening anaphylactic reactions have occurred after isosulfan blue 1% administration. monitor patients closely for at least 60 minutes after administration of isosulfan blue 1% (5.1). the admixture of isosulfan blue 1% with local anesthetics results in an immediate precipitation of 4 to 9% drug complex. use a separate syringe for anesthetics (5.2). isosulfan blue 1% interferes with measurements in peripheral blood pulse oximetry. arterial blood gas analysis may be needed (5.3). 5.1 hypersensitivity reactions life-threatening anaphylactic reactions (respiratory distress, shock, angioedema) have occurred after isosulfan blue 1% administration. reactions are more likely to occur in patients with a history of bronchial asthma, allergies, drug reactions or previous reactions to triphenylmethane dyes. monitor patients closely for at least 60 minutes after administration of isosulfan blue 1%. trained personnel should be available to administer emergency care
including resuscitation. 5.2 precipitation of isosulfan blue 1% by lidocaine the admixture of isosulfan blue 1% (with local anesthetics (i.e. lidocaine)) in the same syringe results in an immediate precipitation of 4 to 9% drug complex. use a separate syringe to administer a local anesthetic. 5.3 interference with oxygen saturation and methemoglobin measurements isosulfan blue 1% interferes with measurements of oxygen saturation in peripheral blood by pulse oximetry and can cause falsely low readings. the interference effect is maximal at 30 minutes and minimal generally by four hours after administration. arterial blood gas analysis may be needed to verify decreased arterial partial pressure of oxygen. isosulfan blue 1% may also cause falsely elevated readings of methemoglobin by arterial blood gas analyzer. therefore, co-oximetry may be needed to verify methemoglobin level.

Dosage and Administration:

2 dosage and administration isosulfan blue injection 1% is to be administered subcutaneously, one-half (1/2) ml into three (3) interdigital spaces of each extremity per study. a maximum dose of 3 ml (30 mg) isosulfan blue is, therefore, injected (2.1). 2.1 subcutaneous administration isosulfan blue injection 1% is to be administered subcutaneously, one-half (1/2) ml into three (3) interdigital spaces of each extremity per study. a maximum dose of 3 ml (30 mg) isosulfan blue is, therefore, injected.

Dosage Forms and Strength:

3 dosage forms and strengths 1% aqueous solution (isosulfan blue) 1% aqueous solution (isosulfan blue)

Contraindications:

4 contraindications isosulfan blue injection 1% is contraindicated in those individuals with known hypersensitivity to triphenylmethane or related compounds. hypersensitivity to triphenylmethane or related compounds (4).

Adverse Reactions:

6 adverse reactions hypersensitivity reactions : hypersensitivity reactions occurring approximately 2% of patients and include life-threatening anaphylactic reactions with respiratory distress, shock, angioedema, urticaria, pruritus. a death has been reported following i.v. administration of a similar compound (6) . to report suspected adverse reactions, contact auromedics pharma llc at 1-866-850-2876 or fda at 1-800-fda-1088 or www.fda.gov/medwatch . 6.1 postmarketing experience hypersensitivity reactions: case series report an overall incidence of hypersensitivity reactions in approximately 2% of patients. life-threatening anaphylactic reactions have occurred. manifestations include respiratory distress, shock, angioedema, urticaria, pruritus. a death has been reported following administration of a similar compound employed to estimate the depth of a severe burn. reactions are more likely to occur in patients with a personal or family history of bronchial asthma, significant allergie
s, drug reactions or previous reactions to triphenylmethane dyes [see warnings and precautions (5)]. laboratory tests: isosulfan blue 1% interferes with measurements of oxygen saturation by pulse oximetry and of methemoglobin by gas analyzer [see warnings and precautions (5)]. skin: transient or long-term (tattooing) blue coloration.

Drug Interactions:

7 drug interactions no drug interactions have been identified with isosulfan blue 1%. no drug interactions have been identified for isosulfan blue 1% (7).

Use in Specific Population:

8 use in specific populations caution should be exercised when isosulfan blue 1% is administered to nursing mothers (8.3). safety and effectiveness of isosulfan blue 1% in children has not been established (8.4). 8.3 nursing mothers it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when isosulfan blue 1% is administered to a nursing mother. 8.4 pediatric use safety and effectiveness of isosulfan blue 1% in children have not been established.

Pediatric Use:

8.4 pediatric use safety and effectiveness of isosulfan blue 1% in children have not been established.

Overdosage:

10 overdosage do not exceed indicated recommended dosage as overdosage levels have not been identified for isosulfan blue 1%.

Description:

11 description the chemical name of isosulfan blue is n-[4-[[4-(diethylamino)phenyl] (2,5-disulfophenyl) methylene]-2,5-cyclohexadien-1-ylidene]-n-ethylethanaminium hydroxide, inner salt, sodium salt. isosulfan blue is a greenish blue color hygroscopic powder. its structural formula is: isosulfan blue injection 1% is a sterile, non-pyrogenic, aqueous dark blue color solution for subcutaneous administration. phosphate buffer in water for injection is added in sufficient quantity to yield a final ph of 6.8 to 7.4. each ml of solution contains 10 mg isosulfan blue, 6.6 mg sodium monohydrogen phosphate and 2.7 mg potassium dihydrogen phosphate. the solution contains no preservative. isosulfan blue injection 1% is a contrast agent for the delineation of lymphatic vessels isosulfan blue chemical structure

Clinical Pharmacology:

12 clinical pharmacology 12.2 pharmacodynamics following subcutaneous administration, isosulfan blue 1% binds to serum proteins and is picked up by the lymphatic vessels. thus, the lymphatic vessels are delineated by the blue dye. 12.3 pharmacokinetics up to 10% of the subcutaneously administered dose of isosulfan blue 1% is excreted unchanged in the urine in 24 hours in human.

Pharmacodynamics:

12.2 pharmacodynamics following subcutaneous administration, isosulfan blue 1% binds to serum proteins and is picked up by the lymphatic vessels. thus, the lymphatic vessels are delineated by the blue dye.

Pharmacokinetics:

12.3 pharmacokinetics up to 10% of the subcutaneously administered dose of isosulfan blue 1% is excreted unchanged in the urine in 24 hours in human.

Nonclinical Toxicology:

13 nonclinical toxicology 13.1 carcinogenesis, mutagenesis, impairment of fertility long-term studies in animals have not been performed to evaluate the carcinogenic potential of isosulfan blue 1%. reproduction studies in animals have not been conducted and, therefore, it is unknown if a problem concerning mutagenesis or impairment of fertility in either males or females exists. 13.2 teratogenic effects pregnancy category c. animal reproduction studies have not been conducted with isosulfan blue 1%. it is not known whether isosulfan blue 1% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. isosulfan blue 1% should be given to a pregnant woman only if clearly needed.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

13.1 carcinogenesis, mutagenesis, impairment of fertility long-term studies in animals have not been performed to evaluate the carcinogenic potential of isosulfan blue 1%. reproduction studies in animals have not been conducted and, therefore, it is unknown if a problem concerning mutagenesis or impairment of fertility in either males or females exists.

How Supplied:

16 how supplied/storage and handling isosulfan blue injection 1% is a sterile, non-pyrogenic, aqueous dark blue color solution and is supplied as follows: isosulfan blue injection 1% 50 mg per 5 ml (10 mg / ml): 5 ml single-dose vials in a carton of 6 ndc 55150-240-05 store at 20° to 25°c (68° to 77°f) [see usp controlled room temperature]. avoid excessive heat. discard unused portion. the vial stoppers are not made with natural rubber latex.

Information for Patients:

17 patient counseling information inform patients that urine color may be blue for 24 hours following administration of isosulfan blue injection 1%. distributed by: auromedics pharma llc 279 princeton-hightstown rd. e. windsor, nj 08520 manufactured by: eugia pharma specialities limited hyderabad - 500032 india

Package Label Principal Display Panel:

Package label-principal display panel - 1% [50 mg per 5 ml (10 mg / ml)] - container label rx only ndc 55150-240-05 isosulfan blue injection 1% 50 mg per 5 ml (10 mg / ml) for lymphography for subcutaneous use only 5 ml single dose vial package label-principal display panel - 1% [50 mg per 5 ml (10 mg / ml)] - container label

Package label-principal display panel - 1% [50 mg per 5 ml (10 mg / ml)] - container-carton (6 vials) rx only ndc 55150-240-05 isosulfan blue injection 1% 50 mg per 5 ml (10 mg / ml) for lymphography for subcutaneous use only sterile 6 x 5 ml non-pyrogenic single dose vials auromedics package label-principal display panel - 1% [50 mg per 5 ml (10 mg / ml)] - container-carton (6 vials)


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.